23 October 2023 - In recent months, drug manufacturers and their allies have filed 10 lawsuits attacking one of the Inflation Reduction Act’s core health policy achievements: its plan for Medicare to negotiate drug prices. 

Applying to a select number of especially profitable drugs that have been on the market for at least nine or 13 years, negotiation is intended to arrive at a fair price — at least 25% less than the manufacturer’s price — based on the drug’s proven clinical benefits.

Read Washington Post article